XLO Stock Analysis: Buy, Sell, or Hold?
XLO - Xilio Therapeutics, Inc. Common Stock
$7.83
-0.07 (-0.89%)
▼
5d:
-3.87%
30d:
+1.29%
90d:
+1350.0%
BUY
MODERATE Confidence
Analysis Updated: Jun 10, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Get Alerted When XLO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: XLO shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: XLO shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: XLO is currently trading at $7.83, which is considered slightly low relative to its 30-day fair value range of $7.80 to $8.44. From a valuation perspective, the stock is trading at a discount (Forward PE: -3.0) compared to its historical average (23.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XLO is in a strong uptrend. Immediate support is located at $7.53, while resistance sits at $8.75.
Market Sentiment: XLO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $20.00 (+153.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XLO is in a strong uptrend. Immediate support is located at $7.53, while resistance sits at $8.75.
Market Sentiment: XLO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $20.00 (+153.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$7.80 -
$8.44
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 153.2% below Wall St target ($20.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$7.80 -
$8.44
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$7.53
Resistance Level
$8.75
Current Trend
Strong Uptrend
Technical data as of
Jun 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.05
Wall Street Target
$20.00
(+153.2%)
Revenue Growth (YoY)
331.7%
Profit Margin
-58.5%
PE vs Historical
-3.1 vs 23.0
CHEAP
Share & Embed Analysis
Last updated: June 10, 2026 1:53 PM ET
Data refreshes hourly during market hours. Next update: 2:53 PM
Data refreshes hourly during market hours. Next update: 2:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XLO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$103 | 58 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 57 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$123 | 50 HOLD |